Autologous CD84 Chimeric Antigen Receptor T-Cell Therapy(BRL Medicine)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameAutologous CD84 Chimeric Antigen Receptor T-Cell Therapy(BRL Medicine)

Drug Alias NameRD-IIT-001

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionLeukocyte Antigen CD84 modulatorsT lymphocyte replacements

TargetsLeukocyte Antigen CD84

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesBRL Medicine Inc

China Registration ClassN/A

Develop Information

Active CompaniesBRL Medicine Inc

Inactive CompaniesN/A

Active IndicationsLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A